The promise of artificial intelligence transforming vaccine development faces a reality check in seasonal flu prevention, where computational approaches have yet to demonstrate meaningful superiority over established strain selection methods. This finding challenges the widespread assumption that AI will inevitably improve upon decades-refined public health practices. The Nature Medicine analysis examined AI-driven approaches to predicting which influenza strains should be included in seasonal vaccines, a critical decision that affects hundreds of millions of people annually. Traditional selection relies on global surveillance networks, phylogenetic analysis, and expert assessment of circulating viral variants. AI methods attempted to enhance this process through machine learning algorithms that analyze viral genetic sequences, antigenic properties, and epidemiological patterns. However, the computational approaches failed to consistently outperform conventional selection criteria in predicting which strains would dominate during flu seasons. This represents a significant limitation for AI applications in vaccine development, particularly given the substantial investment in machine learning tools for public health. The findings underscore a broader pattern in medical AI: impressive performance in controlled laboratory settings often doesn't translate to real-world clinical advantages. For seasonal flu vaccines, timing constraints, viral mutation rates, and the inherent unpredictability of influenza evolution may impose fundamental limits on what any predictive system can achieve. The research suggests that while AI may serve as a valuable supplementary tool, the human expertise and global surveillance infrastructure built over decades remains irreplaceable for vaccine strain selection. This has important implications for pandemic preparedness strategies that increasingly rely on computational approaches.